Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.0%

36 terminated/withdrawn out of 327 trials

Success Rate

75.7%

-10.9% vs industry average

Late-Stage Pipeline

11%

35 trials in Phase 3/4

Results Transparency

5 of 112 completed trials have results

Key Signals

76 recruiting5 with results31 terminated5 withdrawn

Enrollment Performance

Analytics

N/A

89(34.4%)

Phase 2

84(32.4%)

Phase 1

47(18.1%)

Phase 3

32(12.4%)

Early Phase 1

4(1.5%)

Phase 4

3(1.2%)

259Total

N/A(89)

Phase 2(84)

Phase 1(47)

Phase 3(32)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (327)

Showing 20 of 327 trials

NCT04017455Phase 2Active Not Recruiting

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

Role: lead

NCT03026140Phase 2Recruiting

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Role: lead

NCT03448835Phase 2Active Not Recruiting

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Role: lead

NCT04425967Not ApplicableActive Not Recruiting

Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas

Role: lead

NCT06284304Not ApplicableCompleted

A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL

Role: lead

NCT05705921Not ApplicableActive Not Recruiting

Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer

Role: lead

NCT06362616Not ApplicableRecruiting

Preoperative Accelerated Partial Breast Irradiation in Patients With Locally Recurrent or Second Primary Breast Cancer

Role: lead

NCT05301881Phase 2Recruiting

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

Role: lead

NCT07808138Phase 2Not Yet Recruiting

RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer

Role: lead

NCT07786051Phase 2Not Yet Recruiting

DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)

Role: lead

NCT07436858Phase 1Not Yet Recruiting

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

Role: lead

NCT06222489Phase 2Recruiting

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

Role: lead

NCT07402343Phase 2Recruiting

Tarlatamab for SCLC Brain Metastases

Role: collaborator

NCT07511933Not ApplicableRecruiting

Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases

Role: lead

NCT06666634Not ApplicableCompleted

Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy

Role: lead

NCT06237920Phase 2Active Not Recruiting

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

Role: lead

NCT05700656Phase 1Active Not Recruiting

Galunisertib Combined With Capecitabine in Advanced CRC With PM

Role: lead

NCT06888817Phase 3Recruiting

Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases

Role: lead

NCT06012734Phase 1Recruiting

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

Role: lead

NCT07663747Phase 2Not Yet Recruiting

Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC

Role: lead